Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Global Biologics Market: Companies-to-Action - Research and Markets

Research and Markets
Posted on: 20 Dec 17

The "Global Biologics MarketCompanies-to-Action" report has been added to Research and Markets' offering.

This study on the "Global Biologics Market: Companies-to-Action" presents an overview of the global biologics landscape with an emphasis on the top 10 leading bio-pharma companies in the market. The study highlights the shifting focus and investments of bio-pharma companies towards biologics discovery and development, which is attributed to the growing demand for innovative therapies as well as the loss of patent exclusivity of the leading pharma products.

Across therapy areas, oncology and diabetes emerge as the key contributing segments alongside immunology and cardiovascular diseases. Several small- to mid-sized companies are increasingly focusing on oncology and immunology segments which have high unmet needs and higher acceptability for innovative therapies. Furthermore, across the biologics sub-segments, monoclonal antibodies (mAb) and bioengineered vaccines are amongst the highest contributing segments, with most companies having a strong focus on developing a mAb pipeline.

On the other hand, cell and gene therapy are expected to show a strong potential, especially across the rare diseases market, with leading companies like Amgen, Sanofi, Pfizer, etc., investing in molecules in the early stages of clinical development. These molecules, if approved, have the potential of becoming key blockbuster products, propelling the market by more than 20% in the next few years.

Alongside industry and academic research collaborations, companies are also focusing on partnering with IT players such as IBM Watson, Intel etc., which provide technologically advanced solutions for conducting clinical trials to support complex drug manufacturing processes, thus creating integrated business models in addition to the above mentioned strategic analysis, a detailed biologic product pipeline, and a SWOT analysis of the key players has been undertaken.

Key Topics Covered:

1. Executive Summary

2. Companies-to-Action Overview

3. Key Biologics Companies Product Pipeline AnalysisRoche: Biologic Product Pipeline Analysis

4. AmgenBiologic Product Pipeline Analysis

5. SanofiBiologic Product Pipeline Analysis

6. AbbvieBiologic Product Pipeline Analysis

7. Novo NordiskBiologic Product Pipeline Analysis

8. Merck & Co.Biologic Product Pipeline Analysis

9. PfizerBiologic Product Pipeline Analysis

10. Johnson & Johnson (JNJ)Biologic Product Pipeline Analysis

11. Eli LillyBiologic Product Pipeline Analysis

12. GlaxoSmithKline (GSK)Biologic Product Pipeline Analysis

13. Growth EnvironmentBusiness Models and Competitive Playbook

14. Growth Opportunities & Companies to Action

Companies Mentioned:

  • Abbvie Amgen
  • Eli Lilly
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck & Co
  • Novo Nordisk
  • Pfizer
  • Roche
  • Sanofi

For more information about this report visit

View source version on

Business Wire

Last updated on: 20/12/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.